Clinical Study | Office of Clinical Research

Ca030-001- A Phase 1/2 First-In-Human Study Of Bms-986249 Alone And In Combination With Nivolumab

Posted Date: Feb 26, 2020

Investigator: Trisha Wise-Draper
Specialties: Cancer, Oncology
Type of Study: Drug

The main goal of this study is to characterize the safety, tolerability, and DLTs and to determine the MTD/RP2D of BMS-986249 administered as monotherapy and in combination with nivolumab in participants with advanced solid tumors.

Criteria:

To Be Eligible: Must Have Advanced Solid Tumor, Ecog 0-1, No Other Concurrent Active Malignancies Or Past Malignancies Within 2 Years, No Allergy To Study Treatments Or Components, No Uncontrolled Cardio Disease Or Active Infection

Keywords:

Phase 1, Advanced

For More Information:

Uc Cancer Center
513-5847698
cancer@uchealth.com

Name*
First Last
Gender*
- Male
- Female
Age*
Phone*
Email*
How did you hear about us?*
Future Communication*
- By submitting this form, I am agreeing to receive future communication about participating in an upcoming research study.
CAPTCHA
This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.
List